Speaker Details

Iltefat H. Hamzavi, MD, FAAD

Iltefat H. Hamzavi, MD, FAAD

SESSIONS

U009 In Office Surgical Techniques for the Treatment of Moderate to Severe Hidradenitis Suppurativa (HS)
Mar 27, 2026 • 7:30 AM - 8:30 AM • Mile High 4D
S038 Vitiligo
Mar 28, 2026 • 1:00 PM - 4:00 PM • Mile High 2B
P002 Annual Business Meeting and Plenary
Mar 29, 2026 • 9:30 AM - 12:00 PM • Bellco Theatre 3
F074 Challenging Skin Disorders of Hands and Feet
Mar 30, 2026 • 9:00 AM - 11:00 AM • Mile High 1D

DISCLOSURES

AbbVie – Advisory Board(Fees); Almirall – Consultant (1099 relationship)(Fees); Avita – Investigator(Grants/Research Funding); Beiersdorf, Inc. – Advisory Board(Fees); Boehringer Ingelheim – Consultant(Fees); Clinuvel – Investigator(Fees); Galderma Laboratories, L.P. – Investigator(Fees); Global Vitiligo Foundation – Board of Directors(No Compensation Received); Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received); Incyte Corporation – Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); L'Oreal USA Inc. – Investigator(Grants/Research Funding); Lenicura – Investigator(Equipment); Merck – Investigator(Grants/Research Funding); MyDerm Portal, Inc – Stockholder(Stock); Novartis – Consultant(Fees); Pfizer Inc. – Investigator(Fees); Sonoma Biotherapeutics – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding); Teva Pharmaceutical Industries Ltd. – Investigator(Fees); UCB – Consultant(Fees); Union Therapeutics – Consultant(Fees); Vimela – Consultant (1099 relationship)(Fees);